Overview

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of KN046 plus platinum-based doublet chemotherapy in previously untreated advanced non-squamous and squamous NSCLC subjects. The study will assess primarily the safety and efficacy of KN046 plus platinum-based doublet chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Pemetrexed